SEC For	m 4 FORM	4	UNITE	D ST/	ATES	SS	ECL	JRITIE	ES AN	ID E	ЕХСНА	NGE (юмм	ISSION						
								Washi		OMB APPROVAL										
Section 16. Form 4 or Form 5 obligations may continue. See						AT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
																	onse:	0.5		
1. Name and Address of Reporting Person [*] Paolini John F.					<u>K</u> i	inik	tsa Pl		ceutica	als,]	<u>Ltd.</u> [кт		heck all appli Directo V Officer	cable) or (give title	, 10% Owner					
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 02/27/2024								A below)		MEDICAL OFFICER				
C/O KINIKSA PHARMACEUTICALS, LTD. CLARENDON HOUSE 2 CHURCH STREET														6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) HAMILT	Street) HAMILTON D0 HM 11															iled by One Reporting Person iled by More than One Reporting 1				
(City) (State) (Zip)						Rule 10b5-1(c) Transaction Indication														
					X						saction was i ions of Rule			ntract, instructi ion 10.	on or writter	n plan tha	at is intende	d to		
		Tab	ole I - No	on-Deri	vativ	e Se	ecuri	ties Ac	quired	l, Dis	sposed c	of, or Be	neficia	lly Owned	I					
1. Title of Security (Instr. 3) 2. Transac Date (Month/Da					Execution Date,			Transaction D Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4			Benefic Owned	es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount (A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Class A Common Share 02/27/2					7/2024	2024			M ⁽¹⁾		10,156	Α	\$1.8	6 55	55,048		D			
Class A Common Share 02/27/2					7/2024	2024					10,156 E		\$21.03	3 ⁽²⁾ 44	44,892		D			
		•	Table II ·								osed of, converti			y Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transacti Code (Ins 8)				6. Date Exercis Expiration Dat (Month/Day/Ye		te	of Securi Underlyir	ng e Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e (s F illy [g (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershi t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares	1						

Share **M**⁽¹⁾ \$1.86 (3) 02/27/2024 10,156 09/13/2026 Option Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.

2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$21.00 to \$21.09. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Class A

Common Shares

3. The option is fully vested and exercisable.

/s/ Madelyn Zeylikman,

Attorney-in-Fact

10,156

\$<mark>0</mark>

02/29/2024

101,061

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.